Literature DB >> 24740810

TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain.

Natalia Reglińska-Matveyev1, Helena M Andersson1, Suely M Rezende2, Björn Dahlbäck3, James T B Crawley1, David A Lane1, Josefin Ahnström1.   

Abstract

Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the inhibition of activated factor X (FXa). TFPI Kunitz domain 3 residue Glu226 is essential for enhancement of TFPI by protein S. To investigate the complementary functional interaction site on protein S, we screened 44 protein S point, composite or domain swap variants spanning the whole protein S molecule for their TFPI cofactor function using a thrombin generation assay. Of these variants, two protein S/growth arrest-specific 6 chimeras, with either the whole sex hormone-binding globulin (SHBG)-like domain (Val243-Ser635; chimera III) or the SHBG laminin G-type 1 subunit (Ser283-Val459; chimera I), respectively, substituted by the corresponding domain in growth arrest-specific 6, were unable to enhance TFPI. The importance of the protein S SHBG-like domain (and its laminin G-type 1 subunit) for binding and enhancement of TFPI was confirmed in FXa inhibition assays and using surface plasmon resonance. In addition, protein S bound to C4b binding protein showed greatly reduced enhancement of TFPI-mediated inhibition of FXa compared with free protein S. We show that binding of TFPI to the protein S SHBG-like domain enables TFPI to interact optimally with FXa on a phospholipid membrane.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740810      PMCID: PMC4064334          DOI: 10.1182/blood-2014-01-551812

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function.

Authors:  P Nyberg; B Dahlbäck; P García de Frutos
Journal:  FEBS Lett       Date:  1998-08-14       Impact factor: 4.124

2.  Inhibition of cofactor activity of protein S by a complex of protein S and C4b-binding protein. Evidence for inactive ternary complex formation between protein S, C4b-binding protein, and activated protein C.

Authors:  J Nishioka; K Suzuki
Journal:  J Biol Chem       Date:  1990-06-05       Impact factor: 5.157

3.  Unusual ultrastructure of complement-component-C4b-binding protein of human complement by synchrotron X-ray scattering and hydrodynamic analysis.

Authors:  S J Perkins; L P Chung; K B Reid
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

4.  Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein.

Authors:  P Evenäs; P García De Frutos; S Linse; B Dahlbäck
Journal:  Eur J Biochem       Date:  1999-12

5.  Ultrastructure of C4b-binding protein fragments formed by limited proteolysis using chymotrypsin.

Authors:  B Dahlbäck; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1984-10-10       Impact factor: 5.157

6.  Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.

Authors:  G M Willems; M P Janssen; I Salemink; T C Wun; T Lindhout
Journal:  Biochemistry       Date:  1998-03-10       Impact factor: 3.162

7.  Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma.

Authors:  E Castoldi; P Simioni; D Tormene; J Rosing; T M Hackeng
Journal:  J Thromb Haemost       Date:  2009-11-30       Impact factor: 5.824

8.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.

Authors:  N L Sanders; S P Bajaj; A Zivelin; S I Rapaport
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

9.  Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor.

Authors:  T Lindhout; G Willems; R Blezer; H C Hemker
Journal:  Biochem J       Date:  1994-01-01       Impact factor: 3.857

10.  Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-14       Impact factor: 8.311

View more
  14 in total

1.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

2.  Proteomics of Coagulopathy Following Injury Reveals Limitations of Using Laboratory Assessment to Define Trauma-Induced Coagulopathy to Predict Massive Transfusion.

Authors:  Hunter B Moore; Matthew D Neal; Marnie Bertolet; Brian A Joughin; Michael B Yaffe; Christopher D Barrett; Molly A Bird; Russell P Tracy; Ernest E Moore; Jason L Sperry; Brian S Zuckerbraun; Myung S Park; Mitchell J Cohen; Stephen R Wisniewski; James H Morrissey
Journal:  Ann Surg Open       Date:  2022-05-25

3.  Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.

Authors:  Paul E R Ellery; Ida Hilden; Peter Thyregod; Nicholas D Martinez; Susan A Maroney; Joan C Gill; Alan E Mast
Journal:  Haemophilia       Date:  2019-10-14       Impact factor: 4.287

4.  Understanding the functional difference between growth arrest-specific protein 6 and protein S: an evolutionary approach.

Authors:  Romain A Studer; Fred R Opperdoes; Gerry A F Nicolaes; André B Mulder; René Mulder
Journal:  Open Biol       Date:  2014-10       Impact factor: 6.411

5.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

6.  Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk.

Authors:  P Suchon; M Germain; A Delluc; D Smadja; X Jouven; B Gyorgy; N Saut; M Ibrahim; J F Deleuze; M C Alessi; P E Morange; D A Trégouët
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

7.  Defective fibrin deposition and thrombus stability in Bambi-/- mice are mediated by elevated anticoagulant function.

Authors:  James T B Crawley; Argita Zalli; James H Monkman; Anastasis Petri; David A Lane; Josefin Ahnstrom; Isabelle I Salles-Crawley
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

8.  Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.

Authors:  Stella Thomassen; Tom G Mastenbroek; Frauke Swieringa; Kristien Winckers; Marion A H Feijge; Roy Schrijver; Judith M E M Cosemans; Susan A Maroney; Alan E Mast; Tilman M Hackeng; Johan W M Heemskerk
Journal:  Thromb Haemost       Date:  2018-02-16       Impact factor: 5.249

Review 9.  Protein S: function, regulation, and clinical perspectives.

Authors:  Rinku Majumder; Tina Nguyen
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

10.  Protein S K196E mutation reduces its cofactor activity for APC but not for TFPI.

Authors:  Keiko Maruyama; Masashi Akiyama; Toshiyuki Miyata; Koichi Kokame
Journal:  Res Pract Thromb Haemost       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.